Q3 FY2025 · Presentation
TScan Update Call November 2025 · 4 pages
Read TScan Therapeutics, Inc.'s results firsthand
Preview the first 2 pages of this presentation
Create a free account to start reading
Full documents are included with Professional
TScan Therapeutics, Inc.
NNASDAQ:TCRX0.18
USD
-0.03
(-13.43%)
TScan Therapeutics, Inc. Documents
Q3 FY2025 documents
Earnings release
6 pages
Nov 12, 2025
Quarterly report
94 pages
Nov 12, 2025
Presentation
TScan Therapeutics Corporate Deck_November 2025_vF
30 pages
Presentation
ASH 2025 KOL call_vFINAL
30 pages
Presentation
TScan Update Call November 2025
4 pages
Presentation
TScan Therapeutics Corporate Deck_December 2025_vF
30 pages
Press release
TScan Therapeutics Announces Positive Updated Data from the ALLOHA⢠Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
3 pages
Dec 8, 2025
Press release
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
3 pages
Nov 3, 2025